If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
School of Science and Technology, The University of Georgia, Tbilisi, GeorgiaDepartment of Diagnostic & Interventional Radiology of New Hospitals LTD, Tbilisi, Georgia
Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Address correspondence to: Mahboobeh Karimi-Galougahi MD, Department of ENT, Masih Daneshvari Hospital, Neyavran, Darabad, Tehran, Iran, Ph: +98-21-26105242, Fax: +98-21-26105242.
Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Hyposmia/anosmia is common among patients with coronavirus disease-2019 (COVID-19). Various imaging modalities have been used to assess olfactory dysfunction in COVID-19. In this systematic review, we sought to categorize and summarize the imaging data in COVID-19-induced anosmia.
Material and Methods
Eligible articles were included after a comprehensive review using online databases including Google scholar, Scopus, PubMed, Web of science and Elsevier. Duplicate results, conference abstracts, reviews, and studies in languages other than English were excluded.
Results
In total, 305 patients undergoing MRI/functional MRI (177), CT of paranasal sinuses (129), and PET/CT or PET/MRI scans (14) were included. Out of a total of 218 findings reported on MRI, 80 were reported on early (≤ 1 month) and 85 on late (>1 month) imaging in relation to the onset of anosmia. Overall, OB morphology and T2-weighted or FLAIR signal intensity were normal in 68/218 (31.2%), while partial or complete opacification of OC was observed in 60/218 (27.5%). T2 hyperintensity in OB was detected in 11/80 (13.75%) and 18/85 (21.17%) on early and late imaging, respectively. Moreover, OB atrophy was reported in 1/80 (1.25%) on early and in 9/85 (10.58%) on late imaging. Last, among a total of 129 CT scans included, paranasal sinuses were evalualted in 88 (68.21%), which were reported as normal in most cases (77/88, [87.5%]).
Conclusion
In this systematic review, normal morphology and T2/FLAIR signal intensity in OB and OC obstruction were the most common findings in COVID-19-induced anosmia, while paranasal sinuses were normal in most cases. OC obstruction is the likely mechanism for olfactory dysfunction in COVID-19. Abnormalities in OB signal intensity and OB atrophy suggest that central mechanisms may also play a role in late stage in COVID-19-induced anosmia.
Hyposmia/anosmia is relatively common among patients with coronavirus disease-2019 (COVID-19), both as an isolated symptom or concomitant with other systemic or respiratory symptoms (
). Olfactory dysfunction may present as an alteration in the intensity of perceived odor or in odor quality. While hyposmia/anosmia is a frequent symptom associated with COVID-19, it is usually transient, and spontaneously resolves within a few weeks (
The first step in the olfactory perception is activation by odorants of sensory neurons that are located in the olfactory epithelium. This sensory epithelium is located in the olfactory clefts (OC), which are two narrow passages at the upper part of the nasal cavities (
). Various imaging modalities have been used to assess the olfactory dysfunction in COVID-19, mainly by imaging OB and OC, such as with magnetic resonance imaging (MRI) (
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
Yıldız E, Balcı A, Selendili O, Kuzu S. Covid 19 pandemic: paranasal diagnostic imaging in patients with olfactory loss. Research Square, 2020, doi: 10.21203/rs.3.rs-31774/v1.
). These studies have reported a variety of findings, which are at times divergent.
In the present report, we sought to systematically review the imaging studies that have investigated COVID-19-induced olfactory dysfunction and to categorize the data from these studies, including based on the timing of the imaging in relation to the onset of olfactory dysfunction in the course of COVID-19.
MATERIALS AND METHODS
Study Selection and Eligibility Criteria
We identified studies that have used imaging modalities such as brain CT, MRI, or PET in patients with COVID-19, confirmed with reverse transcription-polymerase chain reaction, and a clinical presentation with anosmia or olfactory dysfunction. Relevant studies were searched using MEDLINE (PubMed), Web of Science, Embase (Elsevier), Scopus, and Google Scholar databases (search was undertaken on May 26, 2021). The following medical subject headings and keywords were used: “Coronavirus,” “COVID-19,” “SARS-CoV-19,” “2019-CoV-19,” “radiolog*,” “radiograph*,” “Anosmia,” “Hyposmia,” “Olfactory Bulb,” “Tomography, X-ray Computed,” “CT,” “MRI,” and “PET.” The full list of the keywords that were used for search in the PubMed is provided in the Supplementary Appendix. Duplicates, conference abstracts, reviews, and studies in languages other than English were excluded.
Data Collection and Analysis
The following data from the eligible studies were collected by two independent investigators and were subsequently cross-checked. Disagreements between the investigators were resolved by a third investigator after discussions and reaching consensus. The following information were collected: first author's name, country where the study was conducted, study type, clinical characteristics of participants, clinical presentation of the olfactory dysfunction, findings on brain imaging, and clinical outcomes.
RESULTS
After excluding duplicate search results, titles and abstracts of 1490 studies were assessed, and 50 eligible studies were assessed by full-text review. Thirty-one studies, including seven cohort studies, six case series/reports, two case-control studies, one cross-sectional study, and 15 commentaries, letters to the editor, and short reports were included in the final analysis. The PRISMA flow diagram for study selection is shown in Figure 1.
Figure 1Flow diagram of the study selection process. (Color version of figure is available online.)
Clinical Characteristics of the Study Participants
Types of the studies and clinical characteristics of the patients are summarized in Table 1. In total, 305 patients were included in the studies. Of these participants, 161 (52.8%) were female, 137 (44.9%) male, and gender was not specified in 7 (2.3%). Age of the participants ranged between 13 and 84 years. Olfactory disorder was self-reported in 157 (51.5%) and by objective olfactory tests in 148 (48.5%). 259 (84.9%) patients had olfactory dysfunction (hyposmia/anosmia). Concomitant taste dysfunction was seen in 98 (32.1%) cases. The most common general symptoms were fever (141, 46.2%), cough (128, 41.9%), myalgia (120, 39.3%), headache (111, 36.3%), dyspnea (98, 32.1%), asthenia/fatigue (38, 12.4%), and gastrointestinal symptoms (21, 6.8%). Other clinical findings (rhinorrhea, coriza, nasal obstruction and facial pain) were less frequently reported.
Table 1Design of the Imaging Studies and Ear, Nose, Throat and Neurological Symptoms in Patients with Olfactory Dysfunction Secondary to COVID-19
Yıldız E, Balcı A, Selendili O, Kuzu S. Covid 19 pandemic: paranasal diagnostic imaging in patients with olfactory loss. Research Square, 2020, doi: 10.21203/rs.3.rs-31774/v1.
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
In total, 14 studies (74 of 305 patients, 24.3%) reported the outcome of the olfactory symptoms. In 28 of 74 (37.8%) cases with reported outcomes, hyposmia/anosmia persisted at the time of reporting, while in 46 of 74 (62.2%) hyposmia/anosmia was partially or completely resolved.
Imaging Modalities
Findings using various imaging modalities are summarized in Table 2. In total, 305 patients undergoing a total of 320 imaging studies were included. Imaging modalities used to assess changes in the olfactory tract in COVID-19-induced anosmia included MRI/functional MRI (n=177), CT of the paranasal sinuses and brain (n=129), and PET/CT or PET/MRI scans (n=14).
Table 2Findings on Various Imaging Modalities in Patients with Olfactory Dysfunction Secondary to COVID-19
-Olfactory cleft opacification (17) (partial [16], total [1]) -OB morphology: normal (8), mild irregularity with preserved J shape (2), contour lobulations (5), rectangular shape (8) -OB signal intensity: normal (2), diffusely increased signal (9), hyperintense foci (16), hyperintense foci with halo (5), microhemorrhages (4) -Olfactory tract signal abnormality (7), olfactory cortex signal abnormality (5), olfactory nerve morphology: normal (13), evident clumping (8), thinning with scarcity (2)
Olfactory cleft opacification: partial (16), total (1), normal olfactory cleft (6) Normal ethmoid air cells and nasal cavity (no opacification) in all cases (23)
Intraneural hyperintensity (4), normal olfactory recess (12), Normal OB morphology and signal intensity (12), hypersignal orbitofrontal and entorhinal cortex (1)
Normal OB morphology and signal intensity (14) (4 normosmic and 10 anosmic patients) Olfactory cleft obstruction (10) (1 normosmic and 9 anosmic patients)
Yıldız E, Balcı A, Selendili O, Kuzu S. Covid 19 pandemic: paranasal diagnostic imaging in patients with olfactory loss. Research Square, 2020, doi: 10.21203/rs.3.rs-31774/v1.
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
Olfactory bulb or cortical hyperintensity were reported on 2D or 3D fluid-attenuated inversion recovery or T2-weighted images. Enhancement was reported based on T1-weighted images following administration of gadolinium-based contrasts.
A summary of the findings on MRI in anosmia of COVID-19 is provided in Tables 2 and 3. In total, 218 MRI findings were reported. Abnormalities on MRI can be divided into the following categories: changes in the morphology and signal intensity in OB, OC, or cortex, and abnormalities on functional MRI. With regard to the timing of imaging in relation to the onset of olfactory symptoms, the studies can be categorized to early imaging (≤1 month since the onset of olfactory dysfunction) and late imaging (> 1 month). Of the total of 218 MRI findings, 80 were detected in the early and 85 in the late phase, while the timing was not specified in the remainder (n=53) (Table 4).
Table 3Findings on MRI in Patients with Olfactory Dysfunction Secondary to COVID-19
Ref
NLOB
OB Enhancement
Hypersignal OB/Tract
Hyposignal OB/Microbleed
OBAtrophy
NLOC
OC Oblitertaion
OM Enhancement
Hypersignal Cortex
4
-
-
1
-
1
-
-
-
1
5
-
4
-
1
-
-
-
-
-
6
-
-
-
-
1
-
-
-
-
7
-
1
-
-
-
-
-
-
-
8
-
1
-
-
-
1
19
-
-
9
3
-
-
-
-
-
-
-
-
10
23
-
17
4
-
-
17
-
5
11
5
-
-
-
-
-
-
-
1
12
12
-
4
-
-
-
-
-
1
13
1
-
-
-
-
-
-
-
-
14
14
-
-
-
-
-
10
-
-
15
1
-
-
-
-
-
-
-
-
16
-
-
-
-
7
-
4
1
-
17
-
-
1
-
-
-
-
-
-
18
-
-
1
-
-
-
1
-
-
19
-
-
1
-
1
-
-
-
-
20
-
-
1
-
-
-
-
-
-
21
-
-
1
-
-
-
-
-
-
22
3
-
-
-
-
4
8
-
-
23
1
-
-
-
-
-
1
-
-
24
1
-
-
-
-
-
-
-
-
25
1
-
-
-
-
-
-
-
-
26
2
-
2
-
-
-
-
-
2
27
1
-
-
-
-
-
-
-
-
28
-
12
-
12
-
-
-
-
-
Total n=218
68 31.2%
18 8.25%
29 13.3%
17 7.8%
10 4.6%
5 2.3%
60 27.5%
1 0.45%
10 4.6%
NL, Normal; NR, not reported; OB, Olfactory bulb; OC, Olfactory cleft; OM, Olfactory mucosa.
Olfactory bulb or cortical hyperintensity were reported on 2D or 3D fluid-attenuated inversion recovery or T2-weighted images. Enhancement was reported based on T1-weighted images following administration of gadolinium-based contrasts.
Of the total of 218 findings on MRI, both morphology and signal intensity of OB were normal in 68/218 (31.2%) (Fig 2), which were the most common overall MRI finding (
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
). OB morphology and signal was normal in 28/80 (35%) in the early and in 26/85 (30.6%) on late imaging, similarly constituting the most common findings on both early and late imaging.
Figure 2A. Coronal T2-weighted magnetic resonance imaging (MRI) of olfactory bulb in a patient with COVID-19-induced anosmia shows rectangular shape of both olfactory bulbs (arrow). Adapted from Kandemirli et al (
) with permission. B. Coronal nonenhanced T2-weighted MRI of a young man with sudden-onset anosmia shows normal olfactory bulb morphology and signal intensity (arrow). Olfactory cleft is also shown (*) with no evidence of mucosal thickening or obliteration. Adapted from Galougahi et al (
). T2 hyperintensity in OB was detected in 11/80 (13.75%) and 18/85 (21.17%) during the early and late imaging, respectively. Moreover, a reduction in the OB volume was detected in 10/218 (4.6%) (
). OB atrophy was reported in one case (1/80 [1.25%]) on early imaging and in none on late imaging (9/85 [10.58%]) (Table 4).
Figure 3(a) Hyperintense foci are noted within both olfactory bulbs of a patient with COVID-19-induced anosmia (arrows). (b) Coronal T2-weighted image at the level of olfactory bulbs revealed bilateral scattered foci of hypointensity (arrows). Both images are adapted from Kandemirli et al (
). OC obliteration was detected in 28/80 (35%) on early imaging and in 22/85 (25.9%) on late imaging. No enhancement in the mucosal lining of OC was detected on early imaging, while this change was only detected in one case (1/85 [1.17%]) in the late phase (
) have been reported. T2 hyperintensity in cortex both on early and late imaging were reported in 6.3% and 5.9% cases, respectively. Bilateral inferior frontal lobe hypodensity involving the straight gyrus was reported in one patient (
Only one report on the use of functional MRI in anosmia secondary to COVID-19 has been published, where strong blood oxygen level-dependent signal within the piriform and right uncal cortices was detected (
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
Findings on CT of paranasal sinuses can be categorized into two main groups: changes in the paranasal sinuses (opacification of the sinuses) or in OC (partial or complete opacification). Among a total of 129 CT scans included in the present review, paranasal sinuses were evaluated and reported in 88 of 129 (68.21%) (
). Moreover, out of the total 129 CT scans, OC was normal in 100/129 (77.5%), while in 29/129 (22.5%) complete or partial opacification of OC was reported (
Yıldız E, Balcı A, Selendili O, Kuzu S. Covid 19 pandemic: paranasal diagnostic imaging in patients with olfactory loss. Research Square, 2020, doi: 10.21203/rs.3.rs-31774/v1.
Few studies using PET/CT for assessment of olfactory dysfunction in COVID-19 have been performed. Reduction in fluorodeoxyglucose uptake in the left insula, left inferior frontal gyrus, left hippocampus and left amigdala compared with the contralateral side were identified in one patient (
). Additionally, hypometabolic activity of the left orbitofrontal cortex was detected in a patient who underwent PET/CT for evaluation of COVID-19-induced olfactory dysfunction (
). Alterantions in glucose metabolism in the olfactory tract and higher brain networks have also been reported in 12 patients with anosmia secondary to COVID-19 (
There was heterogeneity in what has been defined as “control” in the three case-control studies included in the current review. Some studies included normosmic individuals without COVID-19 as the control group (
). In one study, patients with olfactory dysfunction but without COVID-19 were included as controls for imaging evaluation of neurological manifestations of COVID-19 (
) prospectively compared 20 anosmic patients with COVID-19 with 20 age- and sex-matched normosmic individuals without COVID-19 on MRI, which was performed at baseline and 1 month later. There was OC opacification in 19 of 20 cases and in none of the controls at baseline (p<0.001). On repeat MRI, OC opacification was resolved in 12 of 19 and persisted in seven of 12 patients, with the resolution of OC opacification correlating with improved olfaction as assessed by olfactory tests. There was no difference in the OB volume between cases and controls at baseline (p=0.33), and no significant changes in the OB volume were noted in the cases on follow-up MRI (p=0.53). Chetrit et al. (
) prospectively compared 19 patients with COVID-19 and olfactory dysfunction with four patients with COVID-19 and no olfactory dysfunction as controls. There was OC opacification in nine of 19 cases and one of four controls (p value not reported). The OC opacification in one control patient with COVID-19 but without olfactory dysfunction was attributed to initial inflammatory reaction of the nasal mucosa to mild-to-moderate COVID-19. There was higher T2-weighted fluid attenuated inversion recovery (T2 FLAIR) signal intensity in the OB in the cases compared with controls (p<0.001). Last, Strauss et al. (
) retrospectively compared 12 patients with COVID-19 and neurological symptoms with 12 age-matched controls without COVID-19 who had undergone MRI for evaluation of olfactory dysfunction. T2 FLAIR signal intensity in OB was higher in patients with COVID-19 compared to patients with olfactory dysfunction without COVID-19 (p=0.003). Four of 12 patients with COVID-19 demonstrated T2 signal hyperintensity on 3D T2 FLAIR compared to none of the 12 controls with olfactory dysfunction without COVID-19 (p=0.028). OB volume was similar between the two groups (p value not reported).
DISCUSSION
In this systematic review, opacification of OC together with normal OB morphology and signal intensity were the most common imaging findings in patients with olfactory dysfunction secondary to COVID-19, while paranasal sinuses were normal in most cases. OC opacification was detected in most anosmic patients with COVID-19 compared to the normal OC in normosmic controls, with resolution of OC opacification correlating with improved olfaction. Taken together, these data suggest obstruction of OC, which likely results in mixed conductive and peripheral sensory-neural anosmia, as the most likely mechanism for olfactory dysfunction in COVID-19. An increase in the frequency of abnormalities in signal intensity and morphology of OB on late versus early imaging suggests that central mechanisms for anosmia may also play a role, especially in the late phase - a postulate that is supported by functional abnormalities detected on PET and functional MRI studies.
The exact pathogenesis of the olfactory dysfunction in COVID-19 is not fully elucidated. Possible mechanisms include neurotropism and invasion of the OB by the virus, inflammatory changes, and impairment of the olfactory epithelium via angiotensin converting enzyme two receptors that are expressed by the non-neural olfactory supporting cells (
). Persistent olfactory dysfunction after sinonasal symptoms resolve suggests possible injury to the olfactory stem cells and impairment of the supporting cells (
Post-viral ansomia due to upper respiratory tract infections can occur in up to 40% of cases, which is often secondary to diffuse sinonasal mucosal thickening. Nevertheles, sudden, transient olfactory dysfunction is common in COVID-19 (
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
) indicates that diffuse sinonasal mucosal thickening may not be a contributing mechanism in most cases of COVID-19-induced anosmia. Consistent with this, CT of paranasal sinuses was normal in most patients with COVID-19-induced anosmia, with no mucosal thickening or obstruction detected (
Yıldız E, Balcı A, Selendili O, Kuzu S. Covid 19 pandemic: paranasal diagnostic imaging in patients with olfactory loss. Research Square, 2020, doi: 10.21203/rs.3.rs-31774/v1.
Similarly, On MRI, OB and OC were normal in most cases with COVID-19-induced anosmia. Nevertheless, infection of the olfactory epithelial support cells (Bowman and sustentacular cells) plays a key role in ansomia of COVID-19 (
). SARS-CoV-2 utilizes angiotensin converting enzyme 2 and transmembrane serine protease 2 to enter the respiratory epithelial cells, which act as a viral reservoir for COVID-19 (
). The localized respiratory epithelial involvement and inflammation in the OC may appear as hyperintense mucosal thickening and obstruction, which indeed was the second most common abnormality on MRI in the present review. It is postulated that patients with obstruction in the OC may develop more severe olfactory dysfunction compared with patients with normal OC (
Inflammation of the OB with blood brain barrier breakdown can result in edema in OB, which appears as hypersignal intensity on T2-weighted images. Prolonged inflammation of the olfactory tract can be detected as thickening and clumped appearance of the olfactory nerve filia on MRI (
). Additionally, microbleeding secondary to microvascular injury and microthrombosis by SARS-Cov-2 may appear as foci of hyposignal intensity within the OB (
Overall, timing of the imaging studies during the course of COVID-19-induced olfactory dysfunction appears to be important in detection of abnormalities on imaging. While imaging of OB in most cases is normal within the early days after the onset of olfactory dysucntion, a decrease in the OB volume, detected as thinning or loss of normal oval shape and asymmetry compared with the contralateral OB (
), is more frequently detected at later stages. Additionally, it is plausible that persistently low activity in the afferent olfactory neurons may result in further reduction in the OB volume. Indeed, it takes several weeks for structural changes in the OB to appear in the course of COVID-19-induced anosmia. This observation might suggest impairment in the olfactory stem cells in addition to damage to the epithelial support cells (
) may also contribute to the observed hypometabolism on PET-CT.
Limitations: there was significant heterogeneity in the reported studies, which included case reports, case series, retrospective studies as well as prospective controlled and non-controlled studies. Due to the paucity of well-designed prospective studies, case reports and case series reporting the imaging findings in anosmia of COVID-19 constitute a significant proportion of the available data and were therefore included in the present review. Other limitations include incomplete reporting of demographics and timing of the imaging studies in relation to the onset of olfactory dysfunction and a lack of systemic follow-up in some studies.
CONCLUSION
This systematic review suggests that focal mucosal thickening and obstruction of OC plays a dominant mechanistic role in COVID-19-induced olfactory dysfunction. Hyperintensity in the OB, OB atrophy, cortical hyperintensity, and hypometabolic cortical activity indicate a central mechanism at later stages, likely due to the direct neurotropism of SARS-CoV-2. Further studies are needed to elucidate the exact pathogenesis and the full spectrum of imaging manifestations during the evolution of olfactory dysfunction secondary to COVID-19.
Author Contributions
Study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; approval of the final version of the submitted manuscript, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, P.K., F.Y., S.H.; and manuscript editing, all authors.
("coronavirus 2" [Title/Abstract] OR "coronavirus 2"[Mesh] OR "coronavirus infections"[Title/Abstract] OR "coronavirus infections"[Mesh] OR "COVID-19"[Title/Abstract] OR "COVID-19"[Mesh] OR "coronavirus"[Title/Abstract] OR "coronavirus"[Mesh] OR "2019-nCoV"[Title/Abstract] OR "COVID-2019"[Title/Abstract] OR "COVID19"[Title/Abstract] OR "nCoV"[Title/Abstract] OR "coronavirus disease 2019"[Title/Abstract] OR "2019 novel coronavirus"[Title/Abstract] OR "severe acute respiratory syndrome"[Title/Abstract] OR "SARS-CoV-19"[Title/Abstract] OR "SARS-CoV-2"[Title/Abstract] OR "2019-CoV-19"[Title/Abstract] OR "SARS-CoV"[Title/Abstract] OR "2019nCoV"[Title/Abstract] OR "coronavirinae"[Title/Abstract] OR "2019 Novel Coronavirus Infection"[Title/Abstract] OR "2019 nCoV Infection"[Title/Abstract] OR "Bat coronavirus"[Title/Abstract] OR "betacoronavirus*"[Title/Abstract] OR "coronavirus Infection Disease 2019"[Title/Abstract] OR "covid*"[Title/Abstract] OR "Novel Coronavirus Pneumonia"[Title/Abstract] OR "Wuhan virus"[Title/Abstract]) AND (Radiology[Mesh] OR Radiology[Title/Abstract] OR "Tomography, X-ray Computed"[Mesh] OR "computed assisted tomography"[Title/Abstract] OR CT[Title/Abstract] OR (computed[Title/Abstract] AND tomograph[Title/Abstract]) OR (x-ray[Title/Abstract] AND computed[Title/Abstract]) OR (imaging[Title/Abstract] AND display[Title/Abstract]) OR "Diagnostic Imaging"[Title/Abstract] OR image*[Title/Abstract] OR imaging[Title/Abstract] OR radiography[Title/Abstract] OR radiolog*[Title/Abstract] OR radiograph*[Title/Abstract] OR MRI[Title/Abstract] OR "Magnetic Resonance Imaging"[Title/Abstract] OR PET[Title/Abstract] OR MRI-PET[Title/Abstract] OR PET/CT[Title/Abstract] OR PET/MR[Title/Abstract] OR PET-CT[Title/Abstract] OR "Positron Emission Tomograph*"[Title/Abstract] OR "FDG PET"[Title/Abstract] OR FDG-PET[Title/Abstract] OR "FDG PET/CT"[Title/Abstract]) AND (Anosmia[Mesh] OR Anosmia[Title/Abstract] OR Olfactory[Title/Abstract] OR "Olfactory Dysfunction"[Title/Abstract] OR "Olfactory Bulb"[Mesh] OR "Olfactory Bulb"[Title/Abstract] OR "Olfactory cortex"[Mesh] OR "Olfactory cortex"[Title/Abstract] OR "Olfactory tract"[Title/Abstract] OR Hyposmia[Title/Abstract] OR Parosmia[Title/Abstract] OR Phantosmia[Title/Abstract] OR "Loss of smell"[Title/Abstract])
Time: 2019 – 2021
References
Mao L
Jin H
Wang M
et al.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China.
Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection.
Yıldız E, Balcı A, Selendili O, Kuzu S. Covid 19 pandemic: paranasal diagnostic imaging in patients with olfactory loss. Research Square, 2020, doi: 10.21203/rs.3.rs-31774/v1.
00364-0&id=gr1.jpg){kind=link}
00364-0&id=gr2.jpg){kind=link}
00364-0&id=gr3.jpg){kind=link}